Abstracts tagged "Outcome measures"

Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Luana Colloca¹, Robert Dworkin², John Farrar³, Leslie Tive⁴, Ed Whalen⁵, Jerry Yang⁴, Lars Viktrup⁶, Mark Brown⁷, Christine West⁷ and Kenneth Verburg⁸, ¹University of Maryland, Baltimore, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, New York, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
Abstract Number: 1887 • ACR Convergence 2020
Spinal Mobility and Function: How Closely Do They Associate in Axial Spondyloarthropathy?
Sinead Maguire¹, Phil Gallagher² and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²St Vincents University Hospital, UCD, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is a form of inflammatory arthritis affecting the axial skeleton. Persistent disease activity can result in restricted spinal mobility over time,…
Abstract Number: 0119 • ACR Convergence 2020
Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes
Donna Jose¹, Micah Yu², Karina Torralba³, Christina Downey⁴, Justin Dunn⁵ and Vinicius Cabido⁵, ¹Loma Linda University Medical Center, Ontario, CA, ²Loma Linda University Medical Center, Loma Linda, CA, ³Loma Linda University School of Medicine, Redlands, CA, ⁴Loma Linda University Medical Center, Redlands, CA, ⁵Loma Linda University Medical Center, Loma Linda
Background/Purpose: Osteoporosis causes significant morbidity, mortality and healthcare burden. There continues to be a care gap in osteoporosis recognition, treatment and prevention. Several healthcare systems…
Abstract Number: 0321 • ACR Convergence 2020
Outcome Measures in Psoriatic Arthritis Registries Are Very Heterogeneous: A Systematic Literature Review of 27 Registries, or 16183 Patients
Krystel Aouad¹, Georgia Moysidou¹, Antsa Rakotozafiarison¹, Bruno Fautrel² and Laure Gossec¹, ¹Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ²Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Psoriatic arthritis (PsA) is a multidimensional inflammatory disease for which multiple outcome measures can be used, to assess disease activity e.g. through composite scores,…
Abstract Number: 0633 • ACR Convergence 2020
Vitamin D Serum Status in a Cohort of COVID-19 Patients
Alberto Sulli¹, Emanuele Gotelli¹, Sabrina Paolino¹, Andrea Casabella¹, Carmen Pizzorni¹, Elisa Alessandri¹, Vanessa Smith² and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy, ²Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium
Background/Purpose: Vitamin D serum levels have been inversely associated with risk of pulmonary infections and autoimmune inflammatory disease activity and severity [1,2]. A possible role…
Abstract Number: 1129 • ACR Convergence 2020
Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis
Emily Rose¹, Marcela Ferrada¹, Kaitlin Quinn², Wendy Goodspeed¹, Laurent Arnaud³ and Peter C. Grayson⁴, ¹Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ³Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, ⁴Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare chronic disabling inflammatory condition primarily affecting cartilage tissue. Self-reported patient outcome measures, which have not been evaluated in…
Abstract Number: 1653 • ACR Convergence 2020
Bilateral vs Unilateral Total Knee Arthroplasty: Racial Variation in Utilization and In-Hospital Major Complication Rates
Bella Mehta¹, Kaylee Ho², Jennifer Bido³, Stavros Memtsoudis³, Michael Parks⁴, Susan Goodman¹, Linda Russell⁵ and Said Ibrahim⁶, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, New York, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁶Weill Cornell Medicine, Cleveland, OH
Background/Purpose: Compared to White Patients, African Americans (AAs) are reported to have lower utilization and higher complication rates outcomes in Unilateral Total knee arthroplasty (UTKA).…
Abstract Number: 1889 • ACR Convergence 2020
Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients
Yvette Farran¹, Alexis Ogdie², John Reveille³ and Mark Hwang⁴, ¹McGovern Medical School at the University of Texas Health Sciences Center, Houston, TX, ²University of Pennsylvania, Philadelphia, PA, ³Department of Internal Medicine, University of Texas, Houston, TX, ⁴McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: The Patient Reported Outcomes Measurement Information System 29-Item Profile Measure (PROMIS-29) is a generic measure of health-related quality of life (HRQOL) that has seven…
Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Mia Glerup¹, Ellen D Arnstad ², Veronika Rypdal ³, Suvi Peltoniemi ⁴, Kristiina Aalto ⁵, Marite Rygg ⁶, Susan Nielsen ⁷, Anders Fasth ⁸, Lillemor Berntson ⁹, Ellen Nordal ³ and Troels Herlin ¹⁰, ¹Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, ³Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ⁴Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, ⁵Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁶Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ⁷Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, ⁸Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
Abstract Number: 341 • 2019 ACR/ARP Annual Meeting
Development of a Multivariable Improvement Measure for Gout
Naomi Schlesinger¹, N. Lawrence Edwards ², Anthony Yeo ³ and Peter Lipsky ⁴, ¹Division of Rheumatology, Department of Medicine, Rutgers, The State University of New Jersey, New Brunswick, NJ, ²Department of Medicine, University of Florida, Gainesville, FL, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Gout is a multifactorial inflammatory disease in which patients experience a wide range of signs and symptoms, including flares, inflammatory arthritis, tophi and disability.…
Abstract Number: 356 • 2019 ACR/ARP Annual Meeting
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Till Uhlig¹, Lars Fridtjof Karoliussen ², Espen A Haavardsholm ², Tore Kvien ¹ and Hilde Hammer ², ¹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ²Diakonhjemmet hospital, Oslo, Norway
Background/Purpose: Urate lowering therapy (ULT) is expected to prevent new gout flares. Treat-to-target ULT is however often not performed, and more evidence on how often…
Abstract Number: 767 • 2019 ACR/ARP Annual Meeting
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Casey A. Rimland¹, Kaitlin Quinn ², Joel S. Rosenblum ³, Mollie Schwartz ⁴, K Bates Gribbons ⁵, Elaine Novakovich ⁶, Antoine Sreih ⁷, Peter Merkel ⁷, Mark A. Ahlman ⁸ and Peter C. Grayson ⁹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, ²Georgetown University Hospital/National Institutes of Health, Washington, DC, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, ⁴University of Maryland, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…
Abstract Number: 1655 • 2019 ACR/ARP Annual Meeting
Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter¹, Cynthia Magro ², Dana Orange ³, Yaxia Zhang ⁴, Phaedra Agius ⁵, Jackie Finik ⁶, Robert Spiera ¹ and Jessica Gordon ¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, ³Rockefeller University, New York, ⁴Hospital for Special Surgery, New York, ⁵New York Genome Center, New York City, ⁶Hospital for Special Surgery, New York, NY, New York, NY
Background/Purpose: The association between systemic sclerosis (SSc) skin histology and clinical findings is not fully characterized. In two SSc trials, we developed a scoring system…
Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Michelle Mulder¹, Alfons den Broeder ¹, Berbke van Ginneken ¹, Elien Mahler ¹, Frank van den Hoogen ¹, Johanna Vriezekolk ¹ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…
Abstract Number: 2840 • 2019 ACR/ARP Annual Meeting
Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy
Didem Saygin¹, Chester Oddis ¹, Nicole Neiman ¹, Diane Koontz ¹, Siamak Moghadam-Kia ¹ and Rohit Aggarwal ¹, ¹University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare, debilitating systemic diseases characterized by proximal muscle weakness, which limit activities of daily living and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].